GLP-1 Drugs Significantly Reduce Weight, BMI, and Insulin Resistance in Women with PCOS | Research

The takeaway

A meta-analysis of RCTs found GLP-1 receptor agonists significantly reduced BMI, body weight, waist circumference, and insulin resistance in PCOS women compared to metformin and placebo, though with increased nausea, vomiting, and dizziness.

All weight measures P<0.0001
GLP-1RAs significantly reduced BMI, weight, waist circumference, WHR, and abdominal girth in PCOS women, along with improved insulin resistance — the metabolic driver of the condition

What the researchers found

GLP-1RAs significantly reduced BMI, body weight, waist circumference, waist-to-hip ratio, and abdominal girth (all P < 0.0001). For glucose homeostasis, they significantly reduced fasting insulin, 2-hour OGTT glucose, and HOMA-IR. HDL was slightly reduced. Hormone levels (DHEAS, SHBG, total/free testosterone, FAI) were unchanged. Safety: increased nausea (P = 0.02), vomiting (P = 0.04), and dizziness (P = 0.03).

Why it matters

PCOS is the most common endocrine disorder in reproductive-age women, and weight management is central to its treatment. Metformin has been the go-to medication but has limited weight loss effects. GLP-1 drugs offer substantially greater weight and metabolic improvements. For PCOS women struggling with weight — which drives insulin resistance, hormonal imbalance, and infertility — GLP-1 drugs could be transformative.

How the study worked

Systematic review and meta-analysis of RCTs from PubMed, EMBASE, Cochrane Library, Web of Science, and Google Scholar through October 2024. Included adult PCOS women treated with GLP-1RAs versus metformin or placebo. Primary outcomes: anthropometric measures. Secondary outcomes: glucose homeostasis, hormones, lipids, and safety.

What this study cannot tell us

The meta-analysis doesn't specify the number of included RCTs or total participants. Most PCOS GLP-1RA trials are small. The lack of hormone level changes may reflect short study durations — hormonal improvements from weight loss can take months. HDL reduction is a concern and needs monitoring. No data on fertility outcomes, menstrual regularity, or long-term PCOS disease course was included. Specific GLP-1RA agents and doses varied across studies.

How to read the evidence

This is a systematic review and meta-analysis of randomized controlled trials — high-quality evidence. The highly significant results (P<0.0001) for anthropometric outcomes provide strong confidence, though the number and size of included trials is not specified in the abstract.

When this study was published

Published in 2025 with literature through October 2024, this meta-analysis captures the current evidence for GLP-1RAs in PCOS — an indication gaining rapid clinical interest as these drugs become more widely available.

The bigger picture

PCOS management is shifting from hormonal approaches (birth control pills) toward metabolic interventions. GLP-1 drugs address the metabolic root of PCOS — insulin resistance and obesity — rather than just managing symptoms. The finding that GLP-1RAs outperform metformin for weight loss in PCOS aligns with the broader repositioning of these drugs as first-line metabolic therapies. The lack of direct hormonal effects suggests the metabolic improvements (weight loss, reduced insulin resistance) may indirectly improve hormonal balance over longer treatment periods.

Questions still open

Would longer GLP-1RA treatment produce measurable improvements in testosterone and other PCOS hormone levels?
Do GLP-1 drugs improve fertility outcomes in overweight PCOS women?
Should GLP-1RAs replace metformin as the first-line metabolic therapy for PCOS?

Common questions

Can GLP-1 drugs help with PCOS?

This meta-analysis provides strong evidence that GLP-1 drugs significantly reduce weight, BMI, and insulin resistance in women with PCOS — all key drivers of the condition. While the drugs didn't directly change hormone levels in the studies reviewed, improving metabolic health often leads to hormonal improvements over time. GLP-1 drugs are not yet specifically approved for PCOS but are increasingly used off-label, especially for overweight PCOS patients.

Are GLP-1 drugs better than metformin for PCOS?

For weight loss and insulin resistance, GLP-1 drugs appear significantly more effective than metformin based on this meta-analysis. However, metformin is much cheaper, has decades of safety data, and has some benefits GLP-1 drugs may not share (like effects on ovulation). The choice depends on individual priorities — if weight loss is the main goal, GLP-1 drugs are superior, but metformin remains a valid first-line option.

Read the original research

Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials.

Scientific reports, 15(1), 16512

View on PubMed ↗Publisher’s paper ↗

Citation

Lin, Shike; Deng, Yan; Huang, Jing; Li, Meiyan; Sooranna, Suren Rao; Qin, Minzhen; Tan, Bing. (2025). Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials.. Scientific reports, 15(1), 16512. https://doi.org/10.1038/s41598-025-99622-4